Patents by Inventor Katalin Urban-Szabo
Katalin Urban-Szabo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7652021Abstract: The present invention relates to the novel compounds of the general formula (I) possessing dipeptidyl peptidase IV enzyme inhibitory activity, pharmaceutical compositions thereof, methods of using said compounds, processes for their preparation and intermediates of the general formulae (II), (IV), (V), (VII), (VIII) and (IX).Type: GrantFiled: February 28, 2006Date of Patent: January 26, 2010Assignee: Sanofi-AventisInventors: Peter Aranyi, Imre Bata, Sandor Batori, Eva Boronkay, Philippe Bovy, Zoltan Kapui, Edit Susan, Tibor Szabo, Katalin Urban-Szabo, Marton Varga
-
Publication number: 20090247745Abstract: The present invention relates to an adenosine A3 receptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II?), (III?), (IV?), (V?), (VI?), (VII?), (VIII?) and (XIII?) and their preparation.Type: ApplicationFiled: June 15, 2009Publication date: October 1, 2009Applicant: SANOFI-AVENTISInventors: Peter ARANYI, Sandor BATORI, Geza TIMARI, Kinga BOER, Zoltan KAPUI, Endre MIKUS, Katalin URBAN-SZABO, Katalin GERBER, Judit VARGANE SZEREDI, Michel FINET
-
Patent number: 7547696Abstract: The present invention relates to an adenosine A3 receptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II?), (III?), (IV?), (V?), (VI?), (VII?), (VIII?) and (XIII?) and their preparation.Type: GrantFiled: January 31, 2006Date of Patent: June 16, 2009Assignee: sanofi-aventisInventors: Peter Aranyi, Sandor Batori, Geza Timari, Kinga Boer, Zoltan Kapui, Endre Mikus, Katalin Urban-Szabo, Katalin Gerber, Judit Vargane Szeredi, Michel Finet
-
Publication number: 20080293745Abstract: The invention relates to a compound of the general formula (I), as defined herein which is useful for the treatment of a pathology in a patient wherein a CCR3 receptor plays a role in the development of the pathology, and pharmaceutical preparations containing such compound. The invention is also directed to a process for preparing the compound of the general formula (I), and intermediate useful in the preparation.Type: ApplicationFiled: March 18, 2008Publication date: November 27, 2008Applicant: SANOFI-AVENTISInventors: Agnes PAPPNE BEHR, Zoltan KAPUI, Peter ARANYI, Sandor BATORI, Veronika BARTANE BODOR, Lajos T. NAGY, Mihalyne Santa, Marton VARGA, Gyorgy FERENCZY, Endre MIKUS, Katalin URBAN-SZABO, Judit VARGANE SZEREDI, Tibor SZABO, Erzsebet WALCZ
-
Publication number: 20080287434Abstract: The invention relates to a compound of the general formula (I), as defined herein which is useful for the treatment of a pathology in a patient wherein a CCR3 receptor plays a role in the development of the pathology, and pharmaceutical preparations containing such compound. The invention is also directed to a process for preparing the compound of the general formula (I), and intermediate useful in the preparation.Type: ApplicationFiled: March 19, 2008Publication date: November 20, 2008Applicant: SANOFI-AVENTISInventors: Agnes PAPPNE BEHR, Zoltan KAPUI, Peter ARANYI, Sandor BATORI, Veronika BARTANE BODOR, Lajos T. NAGY, Mihalyne T. Santa, Marton VARGA, Gyorgy FERENCZY, Endre MIKUS, Katalin URBAN-SZABO, Judit VARGANE SZEREDI, Erzsebet WALCZ, Edit SUSAN
-
Publication number: 20080280961Abstract: The invention relates to a compound of the general formula (I), as defined herein which is useful for the treatment of a pathology in a patient wherein a CCR3 receptor plays a role in the development of the pathology, and pharmaceutical preparations containing such compound. The invention is also directed to a process for preparing the compound of the general formula (I), and intermediate useful in the preparation.Type: ApplicationFiled: March 19, 2008Publication date: November 13, 2008Applicant: SANOFI-AVENTISInventors: Agnes PAPPNE BEHR, Zoltan KAPUI, Peter ARANYI, Sandor BATORI, Veronika BARTANE BODOR, Lajos T. NAGY, Mihalyne Santa, Marton VARGA, Endre MIKUS, Katalin URBAN-SZABO, Judit VARGANE SZEREDI, Tibor SZABO, Edit SUSAN, Marianna KOVACS
-
Publication number: 20080280963Abstract: The invention relates to a compound of the general formula (I), as defined herein which is useful for the treatment of a pathology in a patient wherein a CCR3 receptor plays a role in the development of the pathology, and pharmaceutical preparations containing such compound. The invention is also directed to a process for preparing the compound of the general formula (I), and intermediate useful in the preparation.Type: ApplicationFiled: March 19, 2008Publication date: November 13, 2008Applicant: SANOFI-AVENTISInventors: Agnes PAPPNE BEHR, Zoltan KAPUI, Peter ARANYI, Sandor BATORI, Veronika BARTANE BODOR, Lajos T. NAGY, Mihalyne Santa, Marton VARGA, Endre MIKUS, Katalin URBAN-SZABO, Judit VARGANE SZEREDI, Tibor SZABO, Edit SUSAN, Marianna KOVACS
-
Publication number: 20080255110Abstract: This invention is directed to a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, Z, m, n, o, p and r are as defined herein, its preparation, pharmaceutical composition and use as an adenosine A3 receptor ligand preferably an antagonist.Type: ApplicationFiled: June 17, 2008Publication date: October 16, 2008Applicant: SANOFI-AVENTISInventors: Peter ARANYI, Laszlo BALAZS, Maria BALOGH, Sandor BATORI, Lajos T. NAGY, Geza TIMARI, Kinga BOER, Zoltan KAPUI, Endre MIKUS, Katalin GERBER, Judit VARGANE SZEREDI, Katalin URBAN-SZABO, Erzsebet WALCZ
-
Patent number: 7419977Abstract: This invention is directed to a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, Z, m, n, o, p and r are as defined herein, its preparation, pharmaceutical composition and use as an adenosine A3 receptor ligand preferably an antagonist.Type: GrantFiled: May 16, 2005Date of Patent: September 2, 2008Assignee: Sanofi-AventisInventors: Peter Aranyi, Laszlo Balazs, Maria Balogh, Sandor Batori, Lajos T. Nagy, Geza Timari, Kinga Boer, Zoltan Kapui, Endre Mikus, Katalin Gerber, Judit Vargane Szeredi, Katalin Urban Szabo, Erzsebet Walcz
-
Publication number: 20080161310Abstract: The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.Type: ApplicationFiled: March 5, 2008Publication date: July 3, 2008Applicant: Sanofi-AventisInventors: Peter Aranyi, Laszlo Balazs, Imre Bata, Sandor Batori, Eva Boronkay, Philippe Bovy, Karoly Kanai, Zoltan Kapui, Edit Susan, Tibor Szabo, Lajos T. Nagy, Katalin Urban-Szabo, Marton Varga
-
Publication number: 20080146604Abstract: The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.Type: ApplicationFiled: February 28, 2008Publication date: June 19, 2008Applicant: Sanofi-AventisInventors: Peter Aranyi, Laszlo Balazs, Sandor Batori, Judit Bence, Kinga Boer, Felix Hajdu, Zoltan Kapui, Endre Mikus, Tibor Szabo, Lajos T. Nagy, Geza Timari, Katalin Urban-Szabo, Erzsebet Walcz
-
Patent number: 7365089Abstract: The present invention relates to adenosine A3? receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and theirs salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.Type: GrantFiled: December 17, 2002Date of Patent: April 29, 2008Assignee: Sanofi-AventisInventors: Peter Aranyi, Laszlo Balazs, Sandor Batori, Judit Bence, Kinga Boer, Felix Hajdu, Zoltan Kapui, Endre Mikus, Tibor Szabo, Lajos T. Nagy, Geza Timari, Katalin Urban-Szabo, Erzsebet Walcz
-
Patent number: 7348327Abstract: The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.Type: GrantFiled: March 4, 2003Date of Patent: March 25, 2008Assignee: Sanofi-AventisInventors: Peter Aranyi, Laszlo Balazs, Imre Bata, Sandor Batori, Eva Boronkay, Philippe Bovy, Karoly Kanai, Zoltan Kapui, Edit Susan, Tibor Szabo, Lajos T. Nagy, Katalin Urban-Szabo, Marton Varga
-
Publication number: 20070043037Abstract: The present invention relates to the orexin receptor antagonists of the general formula (I), which are selective to orexin I receptors.Type: ApplicationFiled: August 10, 2006Publication date: February 22, 2007Applicant: SANOFI-AVENTISInventors: Peter ARANYI, Maria BALOGH, Sandor BATORI, Judit BENCE, Michel FINET, Zoltan KAPUI, Christophe PHILIPPO, Tibor SZABO, Zoltan SZLAVIK, Zsuzsanna TOMOSKOZI, Katalin URBAN-SZABO, Olivier VENIER
-
Patent number: 7176213Abstract: The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containings them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and (III) and to the preparation thereof.Type: GrantFiled: December 17, 2002Date of Patent: February 13, 2007Assignee: Sanofi-AventisInventors: Péter Arányi, László Balázs, Mária Balogh, Sándor Bátori, Kinga Boér, Katalin Gerber, Zoltán Kapui, Endre Mikus, Geza Tímári, T. Nagy Lajos, Katalin Urbán-Szabó, Judit Vargáné Szeredi
-
Publication number: 20070021459Abstract: The present invention relates to the orexin receptor antagonists compounds of the general formula (I) as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic application thereof.Type: ApplicationFiled: June 21, 2006Publication date: January 25, 2007Applicant: SANOFI-AVENTISInventors: Michel ALETRU, Peter ARANYI, Maria BALOGH, Sandor BATORI, Judit BENCE, Philippe BOVY, Zoltan KAPUI, Endre MIKUS, Claudie NAMANE, Christophe PHILIPPO, Tibor SZABO, Zsuzsanna TOMOSKOZI, Katalin URBAN-SZABO
-
Publication number: 20060276487Abstract: The present invention relates to the novel compounds of the general formula (I) possessing dipeptidyl peptidase IV enzyme inhibitory activity, pharmaceutical compositions thereof, methods of using said compounds, processes for their preparation and intermediates of the general formulae (II), (IV), (V), (VII), (VIII) and (IX).Type: ApplicationFiled: February 28, 2006Publication date: December 7, 2006Applicant: Sanofi-aventisInventors: Peter Aranyi, Imre Bata, Sandor Batori, Eva Boronkay, Philippe Bovy, Zoltan Kapui, Edit Susan, Tibor Szabo, Katalin Urban-Szabo, Marton Varga
-
Publication number: 20060211689Abstract: The present invention relates to an adenosine A3 receptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II?), (III?), (IV?), (V?), (VI?), (VII?), (VIII?) and (XIII?) and their preparation.Type: ApplicationFiled: January 31, 2006Publication date: September 21, 2006Applicant: sanofi-aventis U.S. LLCInventors: Peter Aranyi, Sandor Batori, Geza Timari, Kinga Boer, Zoltan Kapui, Endre Mikus, Katalin Urban-Szabo, Katalin Gerber, Judit Vargane Szeredi, Michel Finet
-
Patent number: 6969723Abstract: Compounds of general formula (I), wherein R4 and R5 stand for hydrogen atom or form together an 1,3-butadienyl group, optionally substituted by a methylenedioxy group or one or more straight or branched C1-4 alkyl group, straight or branched C1-4 alkoxy group, hydroxy group or halogen atom; are strong adenosine A3 receptor ligands preferably antagonists.Type: GrantFiled: May 29, 2002Date of Patent: November 29, 2005Assignee: Sanofi - AventisInventors: Peter Arányi, László Balázs, Mária Balogh, Imre Bata, Sándor Bátori, Lajos T. Nagy, Geza Tímári, Kinga Boér, Olivier Finance, Zoltán Kapui, Endre Mikus, Zsuzsanna Szamosvölgyi, Gábor Szeleczky, Katalin Urbán-Szabó
-
Publication number: 20050153973Abstract: Heterocyclic amides useful as inhibitors of dipeptylpeptidase-IV (DPP-IV) enzyme, process for the preparation thereof and intermediates therefore.Type: ApplicationFiled: June 11, 2003Publication date: July 14, 2005Inventors: Peter Aranyl, Laszlo Balazs, Imre Bata, Sandor Batori, Eva Boronkay, Zoltan Kapui, Edit Susan, Tibor Szabo, Lajos Nagy, Katalin Urban-Szabo, Marton Varga